Xyrem REMS Grudgingly Approved; FDA Worries About Blocked Generics
This article was originally published in RPM Report
Executive Summary
FDA approves a Risk Evaluation & Mitigation Strategy for Jazz Pharmaceutical’s Xyrem under protest; the agency says the single-pharmacy distribution plan for the narcolepsy treatment has the potential to block generic competitors from the market. FDA and Jazz had been working for seven years to agree to a REMS that confirms to the requirements under the FDA Amendments Act of 2007.
You may also be interested in...
Sharing Information With US FDA Advisory Committee Can Invalidate Patent, Jazz Finds
Federal Circuit rules that material about Xyrem's REMS distribution system provided for advisory committee review constitutes prior art.
REMS Lawsuit Possible After US FDA Approves Generic Xyrem
FDA waives requirement that Roxane's generic use same REMS as the brand; Jazz ‘intends to evaluate all potential challenges.’ Launch of generic still depends on patent litigation.
REMS Lawsuit Possible After US FDA Approves Generic Xyrem
FDA waives requirement that Roxane's generic use same REMS as the brand; Jazz ‘intends to evaluate all potential challenges.’ Launch of generic still depends on patent litigation.